GustavoAlvaMDDFAPA

Psychiatry • Costa Mesa, CA

Founder and Medical Director of ATP Clinical Research

Join to view full profile

Dr. Alva is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Alva's full profile

Already have an account?

Office
3151 Airway Ave Ste T3
Costa Mesa, CA 92626
Phone+1 833-487-2582

Fax+1 714-545-5748
Is this information wrong?

Education & Training

University of California (Irvine)Residency, Psychiatry, 1994 - 1998
Universidad de GuadalajaraClass of 1990

Certifications & Licensure

CA State Medical License 1995 - 2025
TX State Medical License 2017 - 2024
American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext Start of enrollment: 2013 Mar 01
Completed
Phase 2, Phase 3
A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease Start of enrollment: 2017 May 09
Completed
Phase 1, Phase 2
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type Start of enrollment: 2022 Nov 01
Recruiting
Phase 3
Roles: Contact, Principal Investigator
A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD Start of enrollment: 2021 Jun 21
Completed
Phase 1
Roles: Contact, Principal Investigator
Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease Start of enrollment: 2021 Nov 03
Active, not recruiting
Phase 3
Roles: Principal Investigator, Contact
Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease Start of enrollment: 2022 May 12
Active, not recruiting
Phase 2, Phase 3
Roles: Contact
ANC-501 in the Treatment of Adults With Major Depressive Disorder Start of enrollment: 2022 Sep 19
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Clinical characteristics and treatment exposure of patients with marked treatment-resistant unipolar major depressive disorder: A RECOVER trial report.
Charles R Conway, Scott T Aaronson, Harold A Sackeim, Walter Duffy, Mary Stedman, João Quevedo, Rebecca M Allen, Patricio Riva-Posse, Matthew A Berger, Gustavo Alva, M...> ;Brain Stimulation. 2024 Apr 2
4 citations
Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study.
Sagar V Parikh, Scott T Aaronson, Sanjay J Mathew, Gustavo Alva, Charles DeBattista, Stephen Kanes, Robert Lasser, Amy Bullock, Mona Kotecha, JungAh Jung, Fiona Forres...> ;Neuropsychopharmacology. 2024 Jan 1
1 citations
Importance of achieving rapid treatment response in major depressive disorder.
Gustavo Alva> ;CNS Spectrums. 2023 Oct 1
69 citations
Effects of a combined transcranial magnetic stimulation (TMS) and cognitive training intervention in patients with Alzheimer's disease
Marwan N. Sabbagh, Carl H. Sadowsky, Babak Tousi, Marc E. Agronin, Gustavo Alva, Carmel Armon, Charles Bernick, Andrew P. Keegan, Stella Karantzoulis, Eyal Baror, Mora...> ;Alzheimer's & Dementia. 2020 Apr 1
8 citations
An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson's Disease and Depression.
Daryl DeKarske, Gustavo Alva, Jason L. Aldred, Bruce Coate, Marc Cantillon, Lori Jacobi, Rene Nunez, James C. Norton, Victor Abler> ;Journal of Parkinson's Disease. 2020 Jan 1
4 citations
Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
Kevin J Black, Henry Nasrallah, Stuart Isaacson, Mark Stacy, Rajesh Pahwa, Charles H Adler, Gustavo Alva, Jeffrey W Cooney, Daniel Kremens, Matthew A Menza, Jonathan M...> ;CNS Spectrums. 2018 Dec 1
10 citations
Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer's Disease: Post Hoc Analyses From a Randomized, Controlled, Clinical Trial of Patients Treated ...
George T. Grossberg, Gustavo Alva, Suzanne Hendrix, Noel Ellison, Mary Clare Kane, John Edwards> ;Alzheimer Disease and Associated Disorders. 2018 Jul 1
2 citations
The Emerging Role of Pimavanserin in the Management of Parkinson’s Disease Psychosis
Neal Hermanowicz, Gustavo Alva, Fernando Pagan, Alberto J. Espay, Amita Patel, Katya Cruz Madrid, Daniel Kremens, Jim Kenney, Sheila Arquette, Gary Tereso, Maria Lopes...> ;Journal of Managed Care & Specialty Pharmacy. 2017 Jun 21
33 citations
Detection of Amyloid β Signature in the Lens and Its Correlation in the Brain to Aid in the Diagnosis of Alzheimer's Disease.
Charles Kerbage, Carl H. Sadowsky, Pierre N. Tariot, Marc Agronin, Gustavo Alva, F. Darell Turner, Nilan Dennis J, Anne Cameron, Gerald D. Cagle, Paul D. Hartung> ;American Journal of Alzheimer's Disease and Other Dementias. 2015 Dec 1
13 citations
Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Al...
Gustavo Alva, Jeffrey L. Cummings, James E. Galvin, Xiangyi Meng, Drew M. Velting> ;International Journal of Clinical Practice. 2015 May 1
9 citations
Efficacy of higher‐dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale–cognitive subscale: domain and individual item analysis
Gustavo Alva, Richard S. Isaacson, Carl H. Sadowsky, George T. Grossberg, Xiangyi Meng, Monique Somogyi> ;International Journal of Geriatric Psychiatry. 2014 Sep 1
15 citations
A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia
Peter J. Weiden, Leslie Citrome, Gus Alva, Matthew Brams, Ira D. Glick, Richard Jackson, Greg Mattingly, Farid Kianifard, Xiangyi Meng, Linda Pestreich, Marla Hochfeld...> ;Schizophrenia Research. 2014 Mar 1
19 citations
Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses
Gustavo Alva, George T. Grossberg, Frederick A. Schmitt, Xiangyi Meng, Jason T. Olin> ;International Journal of Geriatric Psychiatry. 2011 Apr 1
34 citations
Relative tolerability of Alzheimer's disease treatments.
Gustavo Alva, Jeffrey L. Cummings> ;Psychiatry. 2008 Nov 1
57 citations
Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials.
Martin R. Farlow, Stephen M. Graham, Gustavo Alva> ;Drug Safety. 2008 Jan 1
111 citations
Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression.
Charles DeBattista, Joseph K. Belanoff, Steven Glass, Arif Khan, Robert L. Horne, Christine Blasey, Linda L. Carpenter, Gustavo Alva> ;Biological Psychiatry. 2006 Dec 15
93 citations
Therapeutic Effects of Individualized Alpha Frequency Transcranial Magnetic Stimulation (αTMS) on the Negative Symptoms of Schizophrenia
Yi Jin, Steven G. Potkin, Aaron S. Kemp, Steven T. Huerta, Gustavo Alva, Trung Minh Thai, D. Carreon, William E. Bunney> ;Schizophrenia Bulletin. 2005 Oct 27
24 citations
Alzheimer disease and other dementias
Gustavo Alva, Steven G. Potkin> ;Clinics in Geriatric Medicine. 2003 Nov 1
79 citations
D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine.
Steven G. Potkin, Vincenzo S. Basile, Yi Jin, Mario Masellis, F. Badri, David Keator, Joseph C. Wu, Gustavo Alva, D. Carreon, William E. Bunney, James H. Fallon, James...> ;Molecular Psychiatry. 2003 Jan 1
16 citations
Open-label study of the effect of combination quetiapine/lithium therapy on lithium pharmacokinetics and tolerability.
Steven G. Potkin, Per T. Thyrum, Rimal Bera, Daniel Carreon, Gustavo Alva, Amir H Kalali, Chiao Yeh> ;Clinical Therapeutics. 2002 Nov 1
12 citations
Brain metabolic effects of Neotrofin in patients with Alzheimer's disease.
Steven G. Potkin, Gustavo Alva, David Keator, D. Carreon, Kirsten Fleming, James H. Fallon> ;Brain Research. 2002 Sep 27
39 citations
Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine.
Steven G. Potkin, Per T. Thyrum, Gustavo Alva, D. Carreon, Chiao Yeh, Amir H Kalali, Lisa A. Arvanitis> ;Journal of Clinical Psychopharmacology. 2002 Apr 1
50 citations
The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine.
Steven G. Potkin, Per T. Thyrum, Gustavo Alva, Rimal Bera, Chiao Yeh, Lisa A. Arvanitis> ;Journal of Clinical Psychopharmacology. 2002 Apr 1
152 citations
A PET Study of the Pathophysiology of Negative Symptoms in Schizophrenia
Steven G. Potkin, Gustavo Alva, Kirsten Fleming, Ravi Anand, David Keator, D. Carreon, Michael Doo, Yi Jin, Joseph C. Wu, James H. Fallon> ;The American Journal of Psychiatry. 2002 Feb 1
115 citations
Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease.
Steven G. Potkin, Ravi Anand, Kirsten Fleming, Gustavo Alva, David Keator, D. Carreon, John Messina, Joseph C. Wu, Richard Hartman, James H. Fallon> ;The International Journal of Neuropsychopharmacology. 2001 Sep 1
Join now to see all

Press Mentions

(6-Month Paliperidone Palmitate), First and Only Twice-Yearly Treatment for Adults with SchizophreniaSeptember 1st, 2021
Dollars for Docs Mints a MillionaireMarch 11th, 2013

Hospital Affiliations

Chapman Global Medical CenterOrange, California

GustavoAlvaMDDFAPA

Dr. Alva is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Hospital Affiliations

Viewing the full profile is available to verified healthcare professionals only.